# Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
Canonical URL: https://biopharmsignal.com/news/ATXI/avenue-therapeutics-announces-last-patient-last-visit-in-phase-1b-2a-clinical-trial-of-aj201-for-the-treatment-of-spinal-and-bulbar-muscular-atrophy-kennedy-s-disease
Ticker: ATXI
Company: Avenue Therapeutics
Source: Avenue Therapeutics
Published: 2024-05-16 12:30 EST
Original Source URL: https://ir.avenuetx.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-02-23 13:00 EST — [Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease](https://biopharmsignal.com/news/ATXI/avenue-therapeutics-enters-into-exclusive-worldwide-license-agreement-for-atx-04-a4f2b121) — Source: Avenue Therapeutics
- 2025-11-06 12:00 EST — [Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics](https://biopharmsignal.com/news/ATXI/avenue-therapeutics-announces-acquisition-of-subsidiary-baergic-bio-by-axsome-therapeutics) — Source: Avenue Therapeutics
- 2024-11-14 21:05 EST — [Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights](https://biopharmsignal.com/news/ATXI/avenue-therapeutics-reports-third-quarter-2024-financial-results-and-recent-corporate-highlights) — Source: Avenue Therapeutics
- 2024-10-09 12:30 EST — [Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit](https://biopharmsignal.com/news/ATXI/avenue-therapeutics-to-participate-in-maxim-group-s-2024-healthcare-virtual-summit) — Source: Avenue Therapeutics
- 2024-09-03 12:30 EST — [Avenue Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/ATXI/avenue-therapeutics-to-participate-in-upcoming-investor-conferences) — Source: Avenue Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)